Continuous up to 4 Years Entecavir Treatment of HBV-Infected Adolescents - A Longitudinal Study in Real Life.
This study evaluated the long-term (up to 4 years) efficacy and safety of entecavir ETV treatment and analysed the significance of baseline and on-treatment factors in long-term ETV outcomes in adolescents with chronic hepatitis B (CHB). We determined the cumulative virological and serological outcomes of 44 adolescents with CHB receiving ETV for up to 4 years. To investigate the dynamics of HBV DNA, ALT activity and hepatitis B e antigen (HBeAg) seroconversion over time and their associations with the considered factors, generalized estimating equation (GEE) models were used. The cumulative rates of undetectable HBV DNA (<20 IU/ml) and HBeAg seroconversion after 4 years were 89.7% and 55.4%, respectively. In the study group, we showed that having undetectable HBV DNA at the 6th or 12th month of therapy predicted the achievement of a sustained response rate (SRR, defined as the loss of HBV DNA, loss of HBeAg and ALT normalization) at year 3 of ETV therapy (P = 0.048, OR = 5.83; P = 0.012; OR = 14.57, respectively). The GEE analysis indicated that of the different factors, the duration of ETV therapy had a strong impact on the achievement of virological suppression, HBeAg seroconversion and SRR in adolescents. Each month after the initiation of therapy, the odds of loss of HBV DNA increased by approximately 5% (OR = 1.05, P<0.0001), on average. Additionally, the GEE analysis revealed that adolescents with an age at infection of ≥10 years had 3 times higher odds of achieving undetectable HBV DNA than patients with a younger infection age (OR = 3.67, P = 0.028). None of the ETV-treated patients reported significant adverse effects. ETV is an effective and safe treatment option for adolescents with CHB. Undetectable HBV DNA in the 6th and/or 12th month of ETV treatment and older age at infection could predict maintained virological suppression.
Department of Paediatric Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Małgorzata
M
Pawłowska
Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, Toruń, Poland.
Krzysztof
http://orcid.org/0000-0002-9766-8730
K
Domagalski
Department of Paediatric Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Beata
B
Smok
Provincial Infectious Diseases Hospital, Bydgoszcz, Poland.
Paweł
P
Rajewski
Department of Theoretical Foundations of Biomedical Sciences and Medical Information Technology, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Magdalena
M
Wietlicka-Piszcz
Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Waldemar
W
Halota
Department of Plant Physiology and Biotechnology, Nicolaus Copernicus University, Toruń, Poland.
Andrzej
A
Tretyn
Aliment Pharmacol Ther. 2012 Jun;35(11):1326-35
22506552
Rev Esp Enferm Dig. 2014 May;106(5):305-11
25287232
Hepatology. 2010 Dec;52(6):2192-205
20890947
Pediatr Neonatol. 2016 Oct;57(5):390-395
26806847
Clin Res Hepatol Gastroenterol. 2015 Jun;39(3):366-72
25468548
Arab J Gastroenterol. 2012 Jun;13(2):41-4
22980589
World J Hepatol. 2015 Apr 28;7(6):896-902
25937866
Hepatology. 2011 Aug;54(2):443-51
21563196
Hepatology. 2009 May;49(5 Suppl):S45-55
19399792
Pediatrics. 2009 Nov;124(5):e1007-13
19805457
J Gastroenterol Hepatol. 2014 May;29(5):912-9
24863185
Hepatology. 2010 Feb;51(2):422-30
20049753
Pol J Pathol. 1999;50(4 Suppl 1):5-11
10845001
J Pediatr Gastroenterol Nutr. 2012 Dec;55(6):648-52
22688509
J Hepatol. 2012 Oct;57(4):885-96
22634122
J Hepatol. 2012 Sep;57(3):508-14
22659518
Int J Med Sci. 2013;10(4):427-33
23471472
J Hepatol. 2013 Oct;59(4):814-29
23707367
Hepatology. 2016 Feb;63(2):377-87
26223345
Dig Liver Dis. 2014 Dec;46(12):1103-10
25195086
Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):571-4
21796345